These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 36099273)

  • 1. COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infections, COVID-19 related hospitalizations and deaths, among individuals aged ≥65 years in Portugal: A cohort study based on data-linkage of national registries February-September 2021.
    Machado A; Kislaya I; Rodrigues AP; Sequeira D; Lima J; Cruz C; Leite PP; Matias Dias C; Nunes B
    PLoS One; 2022; 17(9):e0274008. PubMed ID: 36099273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study.
    Gram MA; Nielsen J; Schelde AB; Nielsen KF; Moustsen-Helms IR; Sørensen AKB; Valentiner-Branth P; Emborg HD
    PLoS Med; 2021 Dec; 18(12):e1003874. PubMed ID: 34919548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mRNA vaccine effectiveness against COVID-19-related hospitalisations and deaths in older adults: a cohort study based on data linkage of national health registries in Portugal, February to August 2021.
    Nunes B; Rodrigues AP; Kislaya I; Cruz C; Peralta-Santos A; Lima J; Pinto Leite P; Sequeira D; Matias Dias C; Machado A
    Euro Surveill; 2021 Sep; 26(38):. PubMed ID: 34558406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes.
    Buchan SA; Chung H; Brown KA; Austin PC; Fell DB; Gubbay JB; Nasreen S; Schwartz KL; Sundaram ME; Tadrous M; Wilson K; Wilson SE; Kwong JC
    JAMA Netw Open; 2022 Sep; 5(9):e2232760. PubMed ID: 36136332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes from Delta AY.4.2: Cohort and test-negative study of 5.4 million individuals in Scotland.
    Kerr S; Vasileiou E; Robertson C; Sheikh A
    J Glob Health; 2022 Jul; 12():05025. PubMed ID: 35802764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 vaccine effectiveness among healthcare workers: a hospital-based cohort study.
    Gaio V; Santos AJ; Amaral P; Faro Viana J; Antunes I; Pacheco V; Paiva A; Pinto Leite P; Antunes Gonçalves L; Araújo L; Silva A; Dias C; Kislaya I; Nunes B; Machado A
    BMJ Open; 2023 May; 13(5):e068996. PubMed ID: 37130692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 vaccine effectiveness in children by age groups. A population-based study in Galicia, Spain.
    Mallah N; Pardo-Seco J; Ares-Gómez S; López-Pérez LR; González-Pérez JM; Rosón B; Otero-Barrós MT; Durán-Parrondo C; Nartallo-Penas V; Mirás-Carballal S; Rodríguez-Tenreiro-Sánchez C; Rivero-Calle I; Gómez-Carballa A; Salas A; Martinón-Torres F
    Pediatr Allergy Immunol; 2023 Oct; 34(10):e14037. PubMed ID: 37877845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July-November 2021.
    Starrfelt J; Danielsen AS; Buanes EA; Juvet LK; Lyngstad TM; Rø GØI; Veneti L; Watle SV; Meijerink H
    BMC Med; 2022 Sep; 20(1):278. PubMed ID: 36050718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron.
    Baum U; Poukka E; Leino T; Kilpi T; Nohynek H; Palmu AA
    BMC Infect Dis; 2022 Nov; 22(1):816. PubMed ID: 36335289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
    Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
    PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France.
    Tamandjou Tchuem CR; Auvigne V; Vaux S; Montagnat C; Paireau J; Monnier Besnard S; Gabet A; Benhajkassen N; Le Strat Y; Parent Du Chatelet I; Levy-Bruhl D
    Vaccine; 2023 Mar; 41(13):2280-2288. PubMed ID: 36870880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 vaccine effectiveness against SARS-CoV-2 infection during the Delta period, a nationwide study adjusting for chance of exposure, the Netherlands, July to December 2021.
    van Ewijk CE; Kooijman MN; Fanoy E; Raven SF; Middeldorp M; Shah A; de Gier B; de Melker HE; Hahné SJ; Knol MJ
    Euro Surveill; 2022 Nov; 27(45):. PubMed ID: 36367011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
    Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring COVID-19 vaccine effectiveness against COVID-19 hospitalisation and death using electronic health registries in ≥65 years old population in six European countries, October 2021 to November 2022.
    Kislaya I; Sentís A; Starrfelt J; Nunes B; Martínez-Baz I; Nielsen KF; AlKerwi A; Braeye T; Fontán-Vela M; Bacci S; Meijerink H; Castilla J; Emborg HD; Hansen CH; Schmitz S; Van Evercooren I; Valenciano M; Nardone A; Nicolay N; Monge S;
    Influenza Other Respir Viruses; 2023 Nov; 17(11):e13195. PubMed ID: 38019704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Waning of 2-Dose BNT162b2 and mRNA-1273 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Accounting for Depletion-of-Susceptibles Bias.
    Andrejko KL; Pry JM; Myers JF; Mehrotra M; Lamba K; Lim E; Fukui N; DeGuzman JL; Openshaw J; Watt J; Jain S; Lewnard JA; Covid-Case-Control Study Team OBOTC
    Am J Epidemiol; 2023 Jun; 192(6):895-907. PubMed ID: 36702469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coverage and Estimated Effectiveness of mRNA COVID-19 Vaccines Among US Veterans.
    Young-Xu Y; Korves C; Roberts J; Powell EI; Zwain GM; Smith J; Izurieta HS
    JAMA Netw Open; 2021 Oct; 4(10):e2128391. PubMed ID: 34613401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis.
    Ssentongo P; Ssentongo AE; Voleti N; Groff D; Sun A; Ba DM; Nunez J; Parent LJ; Chinchilli VM; Paules CI
    BMC Infect Dis; 2022 May; 22(1):439. PubMed ID: 35525973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of COVID-19 vaccination programme in the Republic of San Marino: Focus on effectiveness of Gam-Covid-Vac.
    Tonnara G; Piselli P; Cimaglia C; Arlotti M; Sacchini E; Manoni S; Zani A; Muccioli F; Laderchi A; Rabini S; Antinori A; Vaia F; Nicastri E; Girardi E
    Clin Microbiol Infect; 2022 Dec; 28(12):1636-1643. PubMed ID: 35798146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 vaccine effectiveness against hospitalization due to SARS-CoV-2: A test-negative design study based on Severe Acute Respiratory Infection (SARI) sentinel surveillance in Spain.
    Mazagatos C; Delgado-Sanz C; Monge S; Pozo F; Oliva J; Sandonis V; Gandarillas A; Quiñones-Rubio C; Ruiz-Sopeña C; Gallardo-García V; Basile L; Barranco-Boada MI; Hidalgo-Pardo O; Vazquez-Cancela O; García-Vázquez M; Fernández-Sierra A; Milagro-Beamonte A; Ordobás M; Martínez-Ochoa E; Fernández-Arribas S; Lorusso N; Martínez A; García-Fulgueiras A; Sastre-Palou B; Losada-Castillo I; Martínez-Cuenca S; Rodríguez-Del Águila M; Latorre M; Larrauri A;
    Influenza Other Respir Viruses; 2022 Nov; 16(6):1014-1025. PubMed ID: 35880469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.